BWXT Q3 Revenue Up 10% to $953M, EPS $1.11; Backlog Climbs to $8.56B
BWXT is trading near its 52-week low of $123.05 (4.0% above the low).
Summary
BWXT reported Q3 2026 revenue of $953.0 million, up 10.0%, and diluted EPS of $1.11 versus $0.89 a year ago, with backlog rising to $8,556.2 million. The medical business is now classified as held for sale pending an up-to-$800 million sale to Nordic Capital.
Key Events · Earnings and Guidance · BWXT
-
Q3 Revenue Up 10% to $953M
Revenue rose to $952,972 thousand from $866,286 thousand, driven by Commercial Operations up 25.2% to $314,202 thousand and Government Operations up 3.6% to $639,076 thousand.
-
Diluted EPS $1.11 vs $0.89
Operating income increased $18.7 million to $132,077 thousand; nine-month diluted EPS was $3.06 versus $2.57.
-
Backlog Rises to $8.56B
Total backlog reached $8,556.2 million at September 30, 2026, up from $7,261 million at December 31, 2025, including $1,970.9 million of unfunded U.S. Government backlog.
-
Medical Business Held for Sale
The medical business is classified as held for sale with $659.5 million of non-current assets, under a definitive agreement to sell to Nordic Capital for up to $800 million, expected to close in 2026 or Q1 2027.
Analysis · BWXT · Technology
BWXT beat last year across the board in the third quarter: revenue rose 10.0% to $953.0 million and diluted EPS climbed to $1.11 from $0.89, with operating income up $18.7 million to $132.1 million. Commercial Operations did the heavy lifting, up 25.2% on the Precision Components Group acquisition and more inspection and refurbishment work, while Government Operations grew 3.6%. The clearest read on future revenue is backlog, which reached $8,556.2 million, up from $7,261 million at year-end. The offset: the medical business is now booked as held for sale ahead of the up-to-$800 million sale to Nordic Capital, so reported segment results will change shape once that closes, expected in 2026 or the first quarter of 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BWXT was trading at $128.03 on NYSE in the Technology sector, with a market capitalization of approximately $12B. The 52-week trading range was $123.05 to $241.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.